Risk
- •
Estimated incidence of 1-3:100,000.
- •
Mean age of onset is in the 60s, but ALS can occur as early as the 20s.
- •
Disease duration is approximately 3 y from the time of diagnosis to death.
- •
While there is slight male predominance of sporadic spinal ALS, slight female predominance is found in bulbar ALS
- •
Most cases are sporadic but 5% to 10% are familial.
- •
Risk of anesthesia increases as the FVC falls below 50%, ALS pts can be stratified as low risk if the FVC >50%, moderate risk if the FVC is 30% to 50%, and high risk if the FVC <30%.
Overview
- •
Disease of unclear etiology that leads to progressive degeneration of the upper and lower motor neurons causing amyotrophy (muscle wasting) and lateral sclerosis (gliosis of the corticospinal tracts).
- •
Located in the motor cortex (upper motor neurons) and anterior horn (lower motor neurons) of the spinal cord.
- •
ALS has a relenting course that leads to weakness of all skeletal muscles in the body.
- •
Typically, ALS is asymmetric involving the distal extremities first followed by bulbar muscle weakness as the disease progresses.
- •
After diagnosis in an adult, pts are usually wheelchair bound by 18 mo and die after 3-5 y from resp suppression.
- •
Juvenile forms of ALS do exist, present early in life, and are rare.
- •
Upper motor neuron signs include spasticity, hyperactive reflexes, and upgoing plantar response; lower motor neuron signs include muscle atrophy and fasciculations.
- •
Disease does not affect ocular muscles, bladder, bowel, and sensation.
- •
ALS variants include:
- •
Primary lateral sclerosis: Progressive degeneration of upper motor neurons;
- •
Progressive muscular atrophy: Progressive degeneration of lower motor neurons;
- •
Progressive bulbar palsy: Progressive motoneuron loss from lower cranial nerve nuclei and cervical spine.
- •